Nasdaq · CIK 0001438533
TVTX Travere Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $52.13 on Oct 9, 2026, +107% from the 52-week low and -23% from the high.
Last 90 days
Net insider value
-$66M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
9
$66M by 8 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
TVTXOct 9, 2026 · close 52.13
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Travere Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER sell | $335k 5,375 shares | -11% | +175% from low-7% from high | |
| 37Weak | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $3.1M 50,508 shares | -37% | +175% from low-7% from high | |
| 50Moderate | Eric M Dube CHIEF EXECUTIVE OFFICER sell | $25M 400,000 shares | -76% | +175% from low-7% from high | |
| 40Moderate | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER sell | $18M 283,189 shares | -129% | +175% from low-7% from high | |
| 30Weak | Jula Inrig EVP, Head of R&D & CMO sell | $2.8M 44,674 shares | -31% | +175% from low-7% from high | |
| 30Weak | Elizabeth E Reed Chief Legal Officer and GC sell | $2.3M 37,500 shares | -26% | +175% from low-7% from high | |
| 40Moderate | William E. Rote Chief Research Officer sell | $13M 209,048 shares | -108% | +175% from low-7% from high | |
| 25Weak | Jeffrey A Meckler director sell | $1.3M 20,000 shares | -18% | +196% from low-0% from high | |
| 43Moderate | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $43k 642 shares | -1% | +270% from low-0% from high | |
| 2Weak | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $11k 573 shares | -1% | +60% from low-17% from high | |
| 2Weak | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $8,136 470 shares | -1% | +42% from low-27% from high | |
| 28Weak | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $38k 1,784 shares | -2% | +75% from low-10% from high | |
| 21Weak | Eric M Dube CHIEF EXECUTIVE OFFICER sell | $398k 18,924 shares | -4% | +75% from low-10% from high | |
| 21Weak | Peter Heerma CHIEF COMMERCIAL OFFICER sell | $37k 1,771 shares | -1% | +75% from low-10% from high | |
| 5Weak | Elizabeth E Reed Chief Legal Officer and GC sell | $104k 4,920 shares | -5% | +75% from low-10% from high | |
| 3Weak | William E. Rote Chief Research Officer sell | $67k 3,198 shares | -3% | +75% from low-10% from high | |
| 22Weak | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $631 48 shares | -0% | +18% from low-39% from high | |
| 40Moderate | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER sell | $1.4M 54,244 shares | -74% | - | |
| 33Weak | Eric M Dube CHIEF EXECUTIVE OFFICER sell | $273k 11,375 shares | -3% | - | |
| 6Weak | Peter Heerma CHIEF COMMERCIAL OFFICER sell | $137k 5,642 shares | -4% | - | |
| 22Weak | Jula Inrig CHIEF MEDICAL OFFICER sell | $60k 2,568 shares | -3% | - | |
| 12Weak | Roy D. Baynes director sell | $220k 10,000 shares | -24% | - | |
| 38Weak | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER sell | $67k 3,348 shares | -5% | - | |
| 47Moderate | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $104k 5,192 shares | -5% | - | |
| 50Moderate | Eric M Dube CHIEF EXECUTIVE OFFICER sell | $1.0M 50,691 shares | -11% | - | |
| 40Moderate | Peter Heerma CHIEF COMMERCIAL OFFICER sell | $104k 5,166 shares | -4% | - | |
| 20Weak | Jula Inrig CHIEF MEDICAL OFFICER sell | $106k 5,273 shares | -6% | - | |
| 19Weak | Roy D. Baynes director sell | $320k 16,000 shares | -34% | - | |
| 30Weak | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER sell | $18k 925 shares | -2% | - | |
| 37Weak | Christopher R. Cline CHIEF FINANCIAL OFFICER sell | $16k 865 shares | -1% | - | |
| 32Weak | Eric M Dube CHIEF EXECUTIVE OFFICER sell | $209k 10,736 shares | -3% | - | |
| 35Weak | Peter Heerma CHIEF COMMERCIAL OFFICER sell | $30k 1,584 shares | -1% | - | |
| 10Weak | Jula Inrig CHIEF MEDICAL OFFICER sell | $48k 2,506 shares | -4% | - | |
| 6Weak | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER sell | $258k 15,000 shares | -21% | - | |
| 17Weak | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER sell | $221k 12,090 shares | -18% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | MOption exercise Common Stock10b5-1 | +2,500 | $27.50 | $69k | 44,853 | 25 d ago |
| Sep 15, 2026 | Elizabeth E Reed Chief Legal Officer and GC | MOption exercise Common Stock10b5-1 | +37,500 | $15.46 | $580k | 142,889 | 25 d ago |
| Sep 15, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock10b5-1 | +95,666 | $23.34 | $2.2M | 528,552 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | MOption exercise Common Stock10b5-1 | +39,000 | $25.25 | $985k | 154,745 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +39,283 | $26.88 | $1.1M | 181,349 | 25 d ago |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | MOption exercise Common Stock10b5-1 | +20,000 | $17.44 | $349k | 138,016 | 25 d ago |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | MOption exercise Common Stock10b5-1 | +32,395 | $8.93 | $289k | 145,165 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +1,381 | $22.40 | $31k | 182,730 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | MOption exercise Common Stock10b5-1 | +1,250 | $22.40 | $28k | 46,103 | 25 d ago |
| Sep 15, 2026 | Elizabeth E Reed Chief Legal Officer and GC | SOpen-market sale Common Stock10b5-1 | -21,926 | $62.03 | $1.4M | 120,963 | 25 d ago |
| Sep 15, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -63,498 | $61.99 | $3.9M | 465,054 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | MOption exercise Common Stock10b5-1 | +39,650 | $17.96 | $712k | 194,395 | 25 d ago |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -27,473 | $62.00 | $1.7M | 110,543 | 25 d ago |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | SOpen-market sale Common Stock10b5-1 | -25,390 | $62.02 | $1.6M | 119,775 | 25 d ago |
| Sep 15, 2026 | Elizabeth E Reed Chief Legal Officer and GC | SOpen-market sale Common Stock10b5-1 | -13,874 | $62.63 | $869k | 107,089 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | SOpen-market sale Common Stock10b5-1 | -63,907 | $61.99 | $4.0M | 130,488 | 25 d ago |
| Sep 15, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -28,796 | $62.66 | $1.8M | 436,258 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | MOption exercise Common Stock10b5-1 | +1,625 | $20.46 | $33k | 47,728 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +36,526 | $8.93 | $326k | 219,256 | 25 d ago |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -20,735 | $62.61 | $1.3M | 89,808 | 25 d ago |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | SOpen-market sale Common Stock10b5-1 | -17,284 | $62.62 | $1.1M | 102,491 | 25 d ago |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,900 | $63.69 | $121k | 87,908 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -71,938 | $62.05 | $4.5M | 147,318 | 25 d ago |
| Sep 15, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -3,102 | $63.64 | $197k | 433,156 | 25 d ago |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | SOpen-market sale Common Stock10b5-1 | -1,600 | $63.69 | $102k | 100,891 | 25 d ago |
| Sep 15, 2026 | Elizabeth E Reed Chief Legal Officer and GC | SOpen-market sale Common Stock10b5-1 | -1,400 | $63.69 | $89k | 105,689 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | SOpen-market sale Common Stock10b5-1 | -29,021 | $62.66 | $1.8M | 101,467 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -4,275 | $62.14 | $266k | 43,453 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | SOpen-market sale Common Stock10b5-1 | -3,000 | $63.65 | $191k | 98,467 | 25 d ago |
| Sep 15, 2026 | Elizabeth E Reed Chief Legal Officer and GC | SOpen-market sale Common Stock10b5-1 | -300 | $65.31 | $20k | 105,389 | 25 d ago |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -400 | $65.31 | $26k | 87,508 | 25 d ago |
| Sep 15, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -270 | $65.31 | $18k | 432,886 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -27,421 | $62.59 | $1.7M | 119,897 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -800 | $62.85 | $50k | 42,653 | 25 d ago |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | SOpen-market sale Common Stock10b5-1 | -400 | $65.31 | $26k | 100,491 | 25 d ago |
| Sep 15, 2026 | Jula Inrig EVP, Head of R&D & CMO | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -32,395 | $0.00 | $0 | 43,605 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -300 | $63.66 | $19k | 42,353 | 25 d ago |
| Sep 15, 2026 | Elizabeth E Reed Chief Legal Officer and GC | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -37,500 | $0.00 | $0 | 0 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | SOpen-market sale Common Stock10b5-1 | -270 | $65.31 | $18k | 98,197 | 25 d ago |
| Sep 15, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock10b5-1 | +195,841 | $23.34 | $4.6M | 628,727 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,400 | $63.65 | $89k | 118,497 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -99,716 | $63.26 | $6.3M | 529,011 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | MOption exercise Common Stock10b5-1 | +350 | $17.96 | $6,286 | 98,547 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,431 | $65.31 | $93k | 117,066 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -1,250 | $0.00 | $0 | 3,750 | 25 d ago |
| Sep 16, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -96,125 | $63.64 | $6.1M | 432,886 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | MOption exercise Common Stock10b5-1 | +55,000 | $15.46 | $850k | 153,547 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +100,000 | $11.25 | $1.1M | 217,066 | 25 d ago |
| Sep 15, 2026 | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -1,625 | $0.00 | $0 | 17,875 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | MOption exercise Common Stock10b5-1 | +57,500 | $26.88 | $1.5M | 211,047 | 25 d ago |
| Sep 17, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock10b5-1 | +108,493 | $23.34 | $2.5M | 541,379 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +55,000 | $15.46 | $850k | 272,066 | 25 d ago |
| Sep 17, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -101,691 | $64.59 | $6.6M | 439,688 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | SOpen-market sale Common Stock10b5-1 | -65,104 | $63.12 | $4.1M | 145,943 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +17,717 | $26.88 | $476k | 289,783 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | SOpen-market sale Common Stock10b5-1 | -47,746 | $63.61 | $3.0M | 98,197 | 25 d ago |
| Sep 17, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock10b5-1 | -6,802 | $64.95 | $442k | 432,886 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -93,604 | $63.25 | $5.9M | 196,179 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -79,113 | $63.65 | $5.0M | 117,066 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -39,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 15, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -95,666 | $0.00 | $0 | 304,334 | 25 d ago |
| Sep 15, 2026 | William E. Rote Chief Research Officer | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -39,650 | $0.00 | $0 | 350 | 25 d ago |
| Sep 16, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -195,841 | $0.00 | $0 | 108,493 | 25 d ago |
| Sep 17, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Common Stock10b5-1 | +8,282 | $22.40 | $186k | 125,348 | 25 d ago |
| Sep 17, 2026 | Eric M Dube CHIEF EXECUTIVE OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -108,493 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -350 | $0.00 | $0 | 0 | 25 d ago |
| Sep 17, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -8,282 | $65.07 | $539k | 117,066 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -55,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -39,283 | $0.00 | $0 | 18,217 | 25 d ago |
| Sep 16, 2026 | William E. Rote Chief Research Officer | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -57,500 | $0.00 | $0 | 0 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -1,381 | $0.00 | $0 | 53,119 | 25 d ago |
| Sep 15, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -36,526 | $0.00 | $0 | 28,474 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -55,000 | $0.00 | $0 | 0 | 25 d ago |
| Sep 16, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -17,717 | $0.00 | $0 | 500 | 25 d ago |
| Sep 17, 2026 | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | MOption exercise Employee stock option (right to buy)derivative10b5-1 | -8,282 | $0.00 | $0 | 44,837 | 25 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | MOption exercise Common Stock10b5-1 | +10,000 | $17.44 | $174k | 101,500 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | MOption exercise Common Stock10b5-1 | +10,000 | $26.52 | $265k | 111,500 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | SOpen-market sale Common Stock10b5-1 | -1,700 | $65.39 | $111k | 109,800 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | SOpen-market sale Common Stock10b5-1 | -1,200 | $66.15 | $79k | 108,600 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | SOpen-market sale Common Stock10b5-1 | -14,000 | $67.46 | $944k | 94,600 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | SOpen-market sale Common Stock10b5-1 | -3,100 | $68.09 | $211k | 91,500 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | 31 d ago |
| Sep 10, 2026 | Jeffrey A Meckler director | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | 31 d ago |
| Sep 2, 2026 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock | -642 | $66.37 | $43k | 118,016 | 39 d ago |
| Sep 3, 2025 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -454 | $18.20 | $8,263 | 92,202 | Sep 5, 2025 |
| Sep 4, 2025 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -119 | $19.71 | $2,345 | 92,083 | Sep 5, 2025 |
| Aug 27, 2025 | Christopher R. Cline CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -470 | $17.31 | $8,136 | 92,656 | Aug 28, 2025 |
| May 15, 2025 | Roy D. Baynes director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 37,500 | May 16, 2025 |
| May 15, 2025 | Suzanne Louise Bruhn director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 28,750 | May 16, 2025 |
| May 15, 2025 | Timothy Coughlin director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 55,500 | May 16, 2025 |
| May 15, 2025 | Brinkley Ruth Williams director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 25,750 | May 16, 2025 |
| May 15, 2025 | Ron Squarer director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 35,375 | May 16, 2025 |
| May 15, 2025 | Sandra Poole director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 30,000 | May 16, 2025 |
| May 15, 2025 | John A Orwin director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 35,375 | May 16, 2025 |
| May 15, 2025 | Gary A Lyons director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 57,500 | May 16, 2025 |
| May 15, 2025 | Jeffrey A Meckler director | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 87,500 | May 16, 2025 |
| May 15, 2025 | Roy D. Baynes director | AGrant or award Stock option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | May 16, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Roy D. Baynesdirector
- Suzanne Louise Bruhndirector
- Timothy Coughlindirector
- Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER
- Christopher R. ClineCHIEF FINANCIAL OFFICER
- Eric M DubeCHIEF EXECUTIVE OFFICER
- Peter HeermaCHIEF COMMERCIAL OFFICER
- Jula InrigEVP, Head of R&D & CMO
- Gary A Lyonsdirector
- Jeffrey A Mecklerceo, officer, director
- John A Orwindirector
- Sandra Pooledirector
- Elizabeth E ReedChief Legal Officer and GC
- William E. RoteChief Research Officer
- Ron Squarerdirector
- Brinkley Ruth Williamsdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.